Cargando…

Therapeutic Management of Pseudomonas aeruginosa Bloodstream Infection Non-Susceptible to Carbapenems but Susceptible to “Old” Cephalosporins and/or to Penicillins

It is unknown as to whether other beta-lactams can be used for bloodstream infections (BSI) resulting from Pseudomonas aeruginosa (PA) which are non-susceptible to one or more carbapenem. We conducted a retrospective cohort study at the Assaf Harofeh Medical Center (AHMC) from January 2010 to August...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaidenstein, Ronit, Miller, Asaf, Tal-Jasper, Ruthy, Ofer-Friedman, Hadas, Sklarz, Menachem, Katz, David E., Lazarovitch, Tsillia, Lephart, Paul R., Mengesha, Bethlehem, Tzuman, Oran, Dadon, Mor, Daniel, Chen, Moran-Gilad, Jacob, Marchaim, Dror
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874623/
https://www.ncbi.nlm.nih.gov/pubmed/29337862
http://dx.doi.org/10.3390/microorganisms6010009
_version_ 1783310194145492992
author Zaidenstein, Ronit
Miller, Asaf
Tal-Jasper, Ruthy
Ofer-Friedman, Hadas
Sklarz, Menachem
Katz, David E.
Lazarovitch, Tsillia
Lephart, Paul R.
Mengesha, Bethlehem
Tzuman, Oran
Dadon, Mor
Daniel, Chen
Moran-Gilad, Jacob
Marchaim, Dror
author_facet Zaidenstein, Ronit
Miller, Asaf
Tal-Jasper, Ruthy
Ofer-Friedman, Hadas
Sklarz, Menachem
Katz, David E.
Lazarovitch, Tsillia
Lephart, Paul R.
Mengesha, Bethlehem
Tzuman, Oran
Dadon, Mor
Daniel, Chen
Moran-Gilad, Jacob
Marchaim, Dror
author_sort Zaidenstein, Ronit
collection PubMed
description It is unknown as to whether other beta-lactams can be used for bloodstream infections (BSI) resulting from Pseudomonas aeruginosa (PA) which are non-susceptible to one or more carbapenem. We conducted a retrospective cohort study at the Assaf Harofeh Medical Center (AHMC) from January 2010 to August 2014. Adult patients with PA-BSI non-susceptible to a group 2 carbapenem but susceptible to ceftazidime or piperacillin (with or without tazobactam), were enrolled. We compared the outcomes of patients who received an appropriate beta-lactam antibiotic (“cases”) to those who received an appropriate non-beta-lactam antibiotic (“controls”). Whole genome sequencing was performed for one of the isolates. Twenty-six patients with PA-BSI met inclusion criteria: 18 received a beta-lactam and 8 a non-beta-lactam (three a fluoroquinolone, two colistin, one a fluoroquinolone and an aminoglycoside, one a fluoroquinolone and colistin, and one colistin and an aminoglycoside). All clinical outcomes were similar between the groups. There were large variations in the phenotypic susceptibilities of the strains. A detailed molecular investigation of one isolate revealed a strain that belonged to MLST-137, with the presence of multiple efflux pumps, OXA-50, and a chromosomally mediated Pseudomonas-derived cephalosporinase (PDC). The oprD gene was intact. Non-carbapenem-β-lactams may still be effective alternatives for short duration therapy (up to 14 days) for BSI caused by a carbapenem non-susceptible (but susceptible to ceftazidime, piperacillin, and/or piperacillin-tazobactam) PA strain. This observation requires further confirmatory analyses. Future molecular investigations should be performed, in order to further analyze additional potential mechanisms for this prevalent phenotype.
format Online
Article
Text
id pubmed-5874623
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-58746232018-04-02 Therapeutic Management of Pseudomonas aeruginosa Bloodstream Infection Non-Susceptible to Carbapenems but Susceptible to “Old” Cephalosporins and/or to Penicillins Zaidenstein, Ronit Miller, Asaf Tal-Jasper, Ruthy Ofer-Friedman, Hadas Sklarz, Menachem Katz, David E. Lazarovitch, Tsillia Lephart, Paul R. Mengesha, Bethlehem Tzuman, Oran Dadon, Mor Daniel, Chen Moran-Gilad, Jacob Marchaim, Dror Microorganisms Article It is unknown as to whether other beta-lactams can be used for bloodstream infections (BSI) resulting from Pseudomonas aeruginosa (PA) which are non-susceptible to one or more carbapenem. We conducted a retrospective cohort study at the Assaf Harofeh Medical Center (AHMC) from January 2010 to August 2014. Adult patients with PA-BSI non-susceptible to a group 2 carbapenem but susceptible to ceftazidime or piperacillin (with or without tazobactam), were enrolled. We compared the outcomes of patients who received an appropriate beta-lactam antibiotic (“cases”) to those who received an appropriate non-beta-lactam antibiotic (“controls”). Whole genome sequencing was performed for one of the isolates. Twenty-six patients with PA-BSI met inclusion criteria: 18 received a beta-lactam and 8 a non-beta-lactam (three a fluoroquinolone, two colistin, one a fluoroquinolone and an aminoglycoside, one a fluoroquinolone and colistin, and one colistin and an aminoglycoside). All clinical outcomes were similar between the groups. There were large variations in the phenotypic susceptibilities of the strains. A detailed molecular investigation of one isolate revealed a strain that belonged to MLST-137, with the presence of multiple efflux pumps, OXA-50, and a chromosomally mediated Pseudomonas-derived cephalosporinase (PDC). The oprD gene was intact. Non-carbapenem-β-lactams may still be effective alternatives for short duration therapy (up to 14 days) for BSI caused by a carbapenem non-susceptible (but susceptible to ceftazidime, piperacillin, and/or piperacillin-tazobactam) PA strain. This observation requires further confirmatory analyses. Future molecular investigations should be performed, in order to further analyze additional potential mechanisms for this prevalent phenotype. MDPI 2018-01-16 /pmc/articles/PMC5874623/ /pubmed/29337862 http://dx.doi.org/10.3390/microorganisms6010009 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zaidenstein, Ronit
Miller, Asaf
Tal-Jasper, Ruthy
Ofer-Friedman, Hadas
Sklarz, Menachem
Katz, David E.
Lazarovitch, Tsillia
Lephart, Paul R.
Mengesha, Bethlehem
Tzuman, Oran
Dadon, Mor
Daniel, Chen
Moran-Gilad, Jacob
Marchaim, Dror
Therapeutic Management of Pseudomonas aeruginosa Bloodstream Infection Non-Susceptible to Carbapenems but Susceptible to “Old” Cephalosporins and/or to Penicillins
title Therapeutic Management of Pseudomonas aeruginosa Bloodstream Infection Non-Susceptible to Carbapenems but Susceptible to “Old” Cephalosporins and/or to Penicillins
title_full Therapeutic Management of Pseudomonas aeruginosa Bloodstream Infection Non-Susceptible to Carbapenems but Susceptible to “Old” Cephalosporins and/or to Penicillins
title_fullStr Therapeutic Management of Pseudomonas aeruginosa Bloodstream Infection Non-Susceptible to Carbapenems but Susceptible to “Old” Cephalosporins and/or to Penicillins
title_full_unstemmed Therapeutic Management of Pseudomonas aeruginosa Bloodstream Infection Non-Susceptible to Carbapenems but Susceptible to “Old” Cephalosporins and/or to Penicillins
title_short Therapeutic Management of Pseudomonas aeruginosa Bloodstream Infection Non-Susceptible to Carbapenems but Susceptible to “Old” Cephalosporins and/or to Penicillins
title_sort therapeutic management of pseudomonas aeruginosa bloodstream infection non-susceptible to carbapenems but susceptible to “old” cephalosporins and/or to penicillins
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874623/
https://www.ncbi.nlm.nih.gov/pubmed/29337862
http://dx.doi.org/10.3390/microorganisms6010009
work_keys_str_mv AT zaidensteinronit therapeuticmanagementofpseudomonasaeruginosabloodstreaminfectionnonsusceptibletocarbapenemsbutsusceptibletooldcephalosporinsandortopenicillins
AT millerasaf therapeuticmanagementofpseudomonasaeruginosabloodstreaminfectionnonsusceptibletocarbapenemsbutsusceptibletooldcephalosporinsandortopenicillins
AT taljasperruthy therapeuticmanagementofpseudomonasaeruginosabloodstreaminfectionnonsusceptibletocarbapenemsbutsusceptibletooldcephalosporinsandortopenicillins
AT oferfriedmanhadas therapeuticmanagementofpseudomonasaeruginosabloodstreaminfectionnonsusceptibletocarbapenemsbutsusceptibletooldcephalosporinsandortopenicillins
AT sklarzmenachem therapeuticmanagementofpseudomonasaeruginosabloodstreaminfectionnonsusceptibletocarbapenemsbutsusceptibletooldcephalosporinsandortopenicillins
AT katzdavide therapeuticmanagementofpseudomonasaeruginosabloodstreaminfectionnonsusceptibletocarbapenemsbutsusceptibletooldcephalosporinsandortopenicillins
AT lazarovitchtsillia therapeuticmanagementofpseudomonasaeruginosabloodstreaminfectionnonsusceptibletocarbapenemsbutsusceptibletooldcephalosporinsandortopenicillins
AT lephartpaulr therapeuticmanagementofpseudomonasaeruginosabloodstreaminfectionnonsusceptibletocarbapenemsbutsusceptibletooldcephalosporinsandortopenicillins
AT mengeshabethlehem therapeuticmanagementofpseudomonasaeruginosabloodstreaminfectionnonsusceptibletocarbapenemsbutsusceptibletooldcephalosporinsandortopenicillins
AT tzumanoran therapeuticmanagementofpseudomonasaeruginosabloodstreaminfectionnonsusceptibletocarbapenemsbutsusceptibletooldcephalosporinsandortopenicillins
AT dadonmor therapeuticmanagementofpseudomonasaeruginosabloodstreaminfectionnonsusceptibletocarbapenemsbutsusceptibletooldcephalosporinsandortopenicillins
AT danielchen therapeuticmanagementofpseudomonasaeruginosabloodstreaminfectionnonsusceptibletocarbapenemsbutsusceptibletooldcephalosporinsandortopenicillins
AT morangiladjacob therapeuticmanagementofpseudomonasaeruginosabloodstreaminfectionnonsusceptibletocarbapenemsbutsusceptibletooldcephalosporinsandortopenicillins
AT marchaimdror therapeuticmanagementofpseudomonasaeruginosabloodstreaminfectionnonsusceptibletocarbapenemsbutsusceptibletooldcephalosporinsandortopenicillins